If you are an investor and would be interested in trial access, the Basic content is available on a two-week trial once the trial subscription agreement is in place.
As of March 24, 2026, the arbitrage metric for non-short-dated US CLOs has improved significantly, reflecting a materially wider four-week moving-average loan discounted spread relative to the widening in liability spreads. At approximately 201 bps, this has returned to levels last seen in early January 2025.
Monday’s BWIC provided useful insight into current trading levels for lower-MVOC EU CLO BB tranches and single-B tranches.
A sample of 1,692 US BSL CLO deals (vintage 2013–1H 2025) is included in this study. Deals with a collateral pool factor below 55% are excluded.
Among the 2012–2021 vintages, only 2.4% of EU CLO BB tranches show an MVOC below 100%, compared with 22.2% for US BSL CLOs. Meanwhile, 25.5% of US BSL deals report negative equity NAV, versus 28.0% for EU CLO deals.
The table below shows the latest notional exposure of US CLO managers to Optiv. Overall exposure across US CLOs has declined from US$129 million to US$97.9 million.
Looking at discounted BSL CLO BB tranches traded via BWICs since 8 January 2026, the tables below summarise DM cover levels, grouped by manager tiering and MVOC, for deals with reinvestment periods ending in 2029/30 and 2026/27.
Among the 2012–2021 vintage deals, only 2.1% of EU CLO BB tranches show an MVOC below 100%, compared with 23% for US BSL CLOs. Coincidentally, around 26.1% of both US BSL and EU CLO deals report negative equity NAV.
US CLOs’ overall exposure to the Tempo Acquisition (Alight Solutions) term loan remains largely unchanged at approximately USD 1.44 billion. As of 6 March 2026, 955 US CLO deals, managed by 65 managers, reported an average deal-level exposure of around 37 bps.
EU CLOs’ overall exposure to the ION Platform term loan is approximately EUR 1.49 billion. As of 6 March 2026, 395 EU CLO deals, managed by 50 managers, reported an average deal-level exposure of around 92 bps.
EU CLOs’ overall exposure to Think-Cell TLs is approximately EUR 416 million. As of 6 March 2026, 161 EU CLO deals, managed by 16 managers, reported an average deal-level exposure of around 66 bps.
As of 6 March 2026, the arbitrage metric for non-short-dated US CLOs has improved significantly, reflecting a materially wider four-week moving-average loan discounted spread relative to the widening in liability spreads. At approximately 202 bps, this has returned to levels last seen in early January 2025.
Below are tables presenting the MVOC (AAA-B) and EQ NAV of EU CLO deals by vintage, based on asset prices as of 2 March 2026.
A sample of 133 deals from the 2024 and 1Q 2025 vintages is used. Each deal’s underlying collateral weighted average spread (WAS) is adjusted for its weighted average price (WAP) as of 2 March 2026. The adjusted WAS also takes par losses into account.
A sample of 106 deals from the 2021 and 1Q 2022 vintages is used. Each deal’s underlying collateral weighted average spread (WAS) is adjusted for its weighted average price (WAP) as of 2 March 2026. The adjusted WAS also takes par losses into account.
EU CLOs’ overall exposure to Adonis TL is approximately EUR 413 million. As of 27 February 2026, 209 EU CLO deals, managed by 25 managers, reported an average deal-level exposure of around 52 bps.
